Hematology NewsFDA grants regular approval to venetoclax for CLL/SLLJune 8, 2018CLLIndolent LymphomaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Hematology NewsVenetoclax plus ibrutinib yields encouraging MRD results in first-line CLLJune 8, 2018CLLIndolent LymphomaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Hematology NewsIbrutinib plus rituximab amped PFS in Waldenström’sJune 1, 2018Indolent LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsOlder CLL and NHL patients are more vulnerable to toxicitiesMay 23, 2018CLLIndolent LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsPhysical inactivity linked to lymphoma riskMay 18, 2018Indolent LymphomaHodgkin LymphomaLymphoma & Plasma Cell Disorders
Hematology News5-year data show deepening response with ibrutinib in CLLMay 11, 2018CLLIndolent LymphomaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Hematology NewsIn young MCL patients, optimal treatment may varyMay 4, 2018Mantle Cell LymphomaIndolent Lymphoma
Hematology NewsEarly results favor combo IL-15/anti-CD20 in indolent NHLMay 3, 2018Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsVenetoclax shows muscle against CLL relapsed after idelalisibApril 18, 2018CLLIndolent LymphomaLeukemia, Myelodysplasia, Transplantation
Hematology NewsFDA grants priority review of follicular lymphoma drugApril 11, 2018Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsUpdated CLL guidelines incorporate a decade of advancesApril 6, 2018CLLIndolent LymphomaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Hematology NewsFDA updates breast implant–associated lymphoma cases, riskMarch 22, 2018T Cell LymphomasIndolent LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsIbrutinib linked to invasive fungal infectionsMarch 7, 2018CLLPatient & Survivor CareLeukemia, Myelodysplasia, TransplantationIndolent LymphomaMantle Cell Lymphoma
Hematology NewsMycosis fungoides increases risk for second cancersFebruary 28, 2018T Cell LymphomasIndolent LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsHigh objective response rate, OS seen with ATA129 in PTLDFebruary 24, 2018Aggressive LymphomasLymphoma & Plasma Cell DisordersIndolent Lymphoma
